Considering our findings in the context of the study by Mita et al. (2018) FLOT and CROSS regimens may enhance anti-tumour immunity through upregulation of CD69 however, this may also contribute to the induction of T cell exhaustion in OGJ in a chemotherapy-driven manner as according to the literature, CD69 signalling not only promotes sustained T cell activation and proliferation but also results in T cell exhaustion (Borrego et al. 1999; Mita et al. 2018). The gene discussed is CD69; the disease is neoplasm.